Guillain–Barré Syndrome (GBS) is a rare neurological disorder in which the body's immune system mistakenly attacks part of its peripheral nervous system—the network of nerves located outside of the brain and spinal cord. GBS can range from a very mild case with a brief weakness to nearly devastating paralysis, leaving the person unable to breathe independently.
Most people eventually recover from even the most severe cases of GBS. After recovery, some people will continue to have some degree of weakness.
There are several types of Guillain–Barré syndrome, classified by the part of the peripheral nerve involved in the condition. The most common type of Guillain–Barré syndrome are:
-
Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP)
-
Miller Fisher syndrome
-
Acute Motor Axonal Neuropathy (AMAN) and Acute Motor‐sensory Axonal Neuropathy (AMSAN)
Guillain–Barré Syndrome Market Analysis
The Guillain–Barré Syndrome market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Guillain–Barré Syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The market segment gives a thorough detail of Guillain–Barré Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Guillain–Barré Syndrome Epidemiology
The Guillain–Barré Syndrome epidemiology division provides insights about historical and current Guillain–Barré Syndrome patient pool and forecasted trends for every seven major countries.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The Guillain–Barré Syndrome Epidemiology part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Guillain–Barré Syndrome Marketed & Emerging Drugs
Drug chapter segment of the Guillain–Barré Syndrome report encloses the detailed analysis of Guillain–Barré Syndrome marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
It also helps to understand the Guillain–Barré Syndrome clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The dynamics of Guillain–Barré Syndrome (GBS) market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world and expected launch of emerging therapies in coming years. Companies across the globe are thoroughly working toward the development of new treatment therapies for GBS.
Some of the emerging therapies in Guillain–Barré Syndrome (GBS) market includes ANX005, CK0801, Imlifidase and others. Key companies in Guillain–Barré Syndrome (GBS) market include Annexon, Cellenkos, Hansa Biopharma, and others.
About Delveinsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.